Monounsaturated Fatty Acid diet associates less gastrointestinal adverse events of pirfenidone: phase IV clinical trial

E. Fontanilles (Hospitalet de Llobregat, Spain), C. Vancheri (Catania, Italy), M. Wijsenbeek (Rotterdam, Netherlands), K. Antoniou (Heraklion, Greece), P. Rivera (Maanchester, United Kingdom), F. Bonella (Essen, Germany), E. Renzoni (London, United Kingdom), A. Anne-Marie (London, United Kingdom), V. Vicens-Zygmunt (Hospitalet de Llobregat, Spain), G. Suarez-Cuartin (Hospitalet de Llobregat, Spain), J. Dorca (Hospitalet de Llobregat, Spain), J. Palma (Hospitalet de Llobregat, Spain), A. Bachs (Hospitalet de Llobregat, Spain), V. Avilés (Barcelona, Spain), C. Tebé (Hospitalet de Llobregat, Spain), J. Shull (Hospitalet de Llobregat, Spain), M. Molina Molina (Hospitalet de Llobregat, Spain)

Source: Virtual Congress 2020 – New clinical insights into idiopathic pulmonary fibrosis
Session: New clinical insights into idiopathic pulmonary fibrosis
Session type: Oral Presentation
Number: 3712
Disease area: Interstitial lung diseases

Congress or journal article abstractWebcastSlide presentationE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
E. Fontanilles (Hospitalet de Llobregat, Spain), C. Vancheri (Catania, Italy), M. Wijsenbeek (Rotterdam, Netherlands), K. Antoniou (Heraklion, Greece), P. Rivera (Maanchester, United Kingdom), F. Bonella (Essen, Germany), E. Renzoni (London, United Kingdom), A. Anne-Marie (London, United Kingdom), V. Vicens-Zygmunt (Hospitalet de Llobregat, Spain), G. Suarez-Cuartin (Hospitalet de Llobregat, Spain), J. Dorca (Hospitalet de Llobregat, Spain), J. Palma (Hospitalet de Llobregat, Spain), A. Bachs (Hospitalet de Llobregat, Spain), V. Avilés (Barcelona, Spain), C. Tebé (Hospitalet de Llobregat, Spain), J. Shull (Hospitalet de Llobregat, Spain), M. Molina Molina (Hospitalet de Llobregat, Spain). Monounsaturated Fatty Acid diet associates less gastrointestinal adverse events of pirfenidone: phase IV clinical trial. 3712

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Supplementation with omega-3 fatty acids and atopy symptoms in infants: a randomized controlled trial
Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy
Year: 2008


Omega-3 polyunsaturated fatty acids and FADS genotype: is personalised prevention of asthma on the horizon?
Source: Eur Respir J, 58 (3) 2101386; 10.1183/13993003.01386-2021
Year: 2021



Oral polyunsaturated fatty acid supplementation as adjuvant therapy for asthmatic children
Source: Annual Congress 2012 - Asthma treatment: efficacy and safety
Year: 2012

Intake of n-3 polyunsaturated fatty acids in childhood, FADS genotype and incident asthma
Source: Eur Respir J, 58 (3) 2003633; 10.1183/13993003.03633-2020
Year: 2021



Late Breaking Abstract: Prenatal n-3, n-6, and trans fatty acids and the risk of eosinophilia and allergic sensitization in children at age 3 years
Source: Annual Congress 2010 - Paediatric asthma treatment and monitoring
Year: 2010



Dietary supplementation over one year with fatty acids reduces inflammatory markers and produces clinical improvement in adults with cystic fibrosis
Source: Annual Congress 2007 - Cystic fibrosis lung disease: what do we measure? What do we know?
Year: 2007


Inhalations of Tranexamic Acid for hemoptysis: A randomized controlled trial
Source: International Congress 2018 – Studies on the mechanisms underlying airway disease
Year: 2018


Effectiveness of omega-3 polyunsaturated fatty acids in combination with acetylsalicylic acid in patients with COPD, complicated by cor pulmonale and the syndrome of blood hypercoagulation
Source: Eur Respir J 2004; 24: Suppl. 48, 59s
Year: 2004

The effect of conjugated linoleic acid supplementation on the nutritional status of COPD patients
Source: International Congress 2016 – Novel avenues in the treatment of COPD II
Year: 2016


Food and fatty acid intake and atopic disease in adults
Source: Eur Respir J 2004; 23: 575-582
Year: 2004



LATE-BREAKING ABSTRACT: The benefits of [italic]Nigella sativa[/italic] oil supplementation on asthma inflammation: A randomised, double-blind, placebo-controlled, phase II trial
Source: International Congress 2016 – Novel strategies on COPD and asthma management
Year: 2016


Effects of long-term supplementation of branched-chain amino acids on muscle metabolism in COPD patients
Source: Eur Respir J 2006; 28: Suppl. 50, 638s
Year: 2006

Effects of n-3 polyunsaturated fatty acids on inflammatory markers in chronic obstructive pulmonary disease
Source: Eur Respir J 2006; 28: Suppl. 50, 39s
Year: 2006

Late Breaking Abstract - Long-term safety and efficacy of benralizumab in severe, uncontrolled asthma: first results of BORA, a randomized, Phase III extension study
Source: International Congress 2018 – Notable Studies in Asthma
Year: 2018



Glucocorticoids correct fatty acids composition in asthma patients. Composition of fatty acids in high density lipoproteins in bronchitis patients
Source: Eur Respir J 2007; 30: Suppl. 51, 145s
Year: 2007

Effect of omega-3 and phosphoethanolamine in patients with asthma
Source: Annual Congress 2009 - Towards improving asthma control
Year: 2009


Late-breaking abstract: Cycloxygenase- and lypoxigenase-dependent generation of omega-3 electrophilic fatty acid-derivatives with anti-inflammatory properties
Source: Annual Congress 2011 - Lung cell biology
Year: 2011

Heart-type fatty acid-binding protein for risk assessment of chronic thromboembolic pulmonary hypertension
Source: Eur Respir J 2008; 31: 1024-1029
Year: 2008



Polyunsaturated fatty acids, lactobacillus bifidus, vitamin A and D in the treatment of IgA immunodeficiency in children with frequent respiratory infections
Source: Eur Respir J 2004; 24: Suppl. 48, 357s
Year: 2004